Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 150-158

  De Mattos Arruda, Leticia ^a,b   Bidard, Francois Clement ^c,d   Won, Helen H ^c   Cortes, Javier ^a,e   Ng, Charlotte K Y ^c   Peg, Vicente ^b,f   Nuciforo, Paolo ^a   Jungbluth, Achim A ^c   Weigelt, Britta ^c   Berger, Michael F ^c   Seoane, Joan ^a,b,g   Reis Filho, Jorge S ^c  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUT CURIE   (France)

^e Medica Scientia Innovation Research (MedSIR)   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

BRCA1; Breast cancer; Clonality; Massively parallel sequencing; Metastasis; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR PAX8;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER LOCALIZATION; CLONAL VARIATION; DESCENDING COLON; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DOSAGE; GENE FREQUENCY; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MIDDLE AGED; MULTIPLE CANCER; NONSENSE MUTATION; OVARY CANCER; OVARY CARCINOMA; PERITONEUM; PHYLOGENETIC TREE; PRIORITY JOURNAL; SIGMOID; SOMATIC MUTATION; TUMOR GENE;

BRCA1; BREAST CANCER; CLONALITY; MASSIVELY PARALLEL SEQUENCING; METASTASIS; OVARIAN CANCER;

BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; OVARY;

EID: 84893025530     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.006     Document Type: Article

References (36)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., Boyault S., Burkhardt B., Butler A.P., Caldas C., Davies H.R., Desmedt C., Eils R., Eyfjord J.E., Foekens J.A., Greaves M., Hosoda F., Hutter B., Ilicic T., Imbeaud S., Imielinsk M., Jager N., Jones D.T., Jones D., Knappskog S., Kool M., Lakhani S.R., Lopez-Otin C., Martin S., Munshi N.C., Nakamura H., Northcott P.A., Pajic M., Papaemmanuil E., Paradiso A., Pearson J.V., Puente X.S., Raine K., Ramakrishna M., Richardson A.L., Richter J., Rosenstiel P., Schlesner M., Schumacher T.N., Span P.N., Teague J.W., Totoki Y., Tutt A.N., Valdes-Mas R., van Buuren M.M., van 't Veer L., Vincent-Salomon A., Waddell N., Yates L.R., Australian Pancreatic Cancer Genome, I., Consortium, I.B.C., Consortium, I.M.-S., PedBrain I., Zucman-Rossi J., Futreal P.A., McDermott U., Lichter P., Meyerson M., Grimmond S.M., Siebert R., Campo E., Shibata T., Pfister S.M., Campbell P.J., Stratton M.R. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
2. Amir E., Miller N., Geddie W., Freedman O., Kassam F., Simmons C., Oldfield M., Dranitsaris G., Tomlinson G., Laupacis A., Tannock I.F., Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012, 30:587-592.
3. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 2013, 368:842-851.
4. Bashashati A., Ha G., Tone A., Ding J., Prentice L.M., Roth A., Rosner J., Shumansky K., Kalloger S., Senz J., Yang W., McConechy M., Melnyk N., Anglesio M., Luk M.T., Tse K., Zeng T., Moore R., Zhao Y., Marra M.A., Gilks B., Yip S., Huntsman D.G., McAlpine J.N., Shah S.P. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 2013, 231:21-34.
5. Castellarin M., Milne K., Zeng T., Tse K., Mayo M., Zhao Y., Webb J.R., Watson P.H., Nelson B.H., Holt R.A. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J. Pathol. 2013, 229:515-524.
6. Cibulskis K., Lawrence M.S., Carter S.L., Sivachenko A., Jaffe D., Sougnez C., Gabriel S., Meyerson M., Lander E.S., Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013, 31:213-219.
7. Crockford A., Jamal-Hanjani M., Hicks J., Swanton C. Implications of intratumour heterogeneity for treatment stratification. J. Pathol. 2013, Epub ahead of print. 10.1002/path.4270.
8. De Mattos-Arruda L., Cortes J., Santarpia L., Vivancos A., Tabernero J., Reis-Filho J.S., Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 2013, 10:377-389.
9. DePristo M.A., Banks E., Poplin R., Garimella K.V., Maguire J.R., Hartl C., Philippakis A.A., del Angel G., Rivas M.A., Hanna M., McKenna A., Fennell T.J., Kernytsky A.M., Sivachenko A.Y., Cibulskis K., Gabriel S.B., Altshuler D., Daly M.J. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011, 43:491-498.
10. Domchek S.M., Bradbury A., Garber J.E., Offit K., Robson M.E. Multiplex genetic testing for cancer susceptibility: out on the high wire without a netα. J. Clin. Oncol. 2013, 31:1267-1270.
11. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
12. Hernandez L., Wilkerson P.M., Lambros M.B., Campion-Flora A., Rodrigues D.N., Gauthier A., Cabral C., Pawar V., Mackay A., A'Hern R., Marchio C., Palacios J., Natrajan R., Weigelt B., Reis-Filho J.S. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J. Pathol. 2012, 227:42-52.
13. Hwang H., Quenneville L., Yaziji H., Gown A.M. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl. Immunohistochem. Mol. Morphol. 2004, 12:122-126.
14. Kinde I., Bettegowda C., Wang Y., Wu J., Agrawal N., Shih Ie M., Kurman R., Dao F., Levine D.A., Giuntoli R., Roden R., Eshleman J.R., Carvalho J.P., Marie S.K., Papadopoulos N., Kinzler K.W., Vogelstein B., Diaz L.A. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl Med. 2013, 5:167ra164.
15. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
16. McDermott U., Downing J.R., Stratton M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 2011, 364:340-350.
17. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010, 20:1297-1303.
18. Natrajan R., Reis-Filho J.S. Next-generation sequencing applied to molecular diagnostics. Expert Rev. Mol. Diagn. 2011, 11:425-444.
19. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., Muthuswamy L., Krasnitz A., McCombie W.R., Hicks J., Wigler M. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
20. Niikura N., Liu J., Hayashi N., Mittendorf E.A., Gong Y., Palla S.L., Tokuda Y., Gonzalez-Angulo A.M., Hortobagyi G.N., Ueno N.T. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 2012, 30:593-599.
21. Nonaka D., Chiriboga L., Soslow R.A. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am. J. Surg. Pathol. 2008, 32:1566-1571.
22. Paradis E., Claude J., Strimmer K. APE: analyses of phylogenetics and evolution in R language. Bioinformatics 2004, 20:289-290.
23. Poduri A., Evrony G.D., Cai X., Walsh C.A. Somatic mutation, genomic variation, and neurological disease. Science 2013, 341:1237758.
24. Pusztai L., Viale G., Kelly C.M., Hudis C.A. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15:1164-1168.
25. Robinson J.T., Thorvaldsdottir H., Winckler W., Guttman M., Lander E.S., Getz G., Mesirov J.P. Integrative genomics viewer. Nat. Biotechnol. 2011, 29:24-26.
26. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
27. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 2012, 22:50-55.
28. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30:e57.
29. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., Bashashati A., Prentice L.M., Khattra J., Burleigh A., Yap D., Bernard V., McPherson A., Shumansky K., Crisan A., Giuliany R., Heravi-Moussavi A., Rosner J., Lai D., Birol I., Varhol R., Tam A., Dhalla N., Zeng T., Ma K., Chan S.K., Griffith M., Moradian A., Cheng S.W., Morin G.B., Watson P., Gelmon K., Chia S., Chin S.F., Curtis C., Rueda O.M., Pharoah P.D., Damaraju S., Mackey J., Hoon K., Harkins T., Tadigotla V., Sigaroudinia M., Gascard P., Tlsty T., Costello J.F., Meyer I.M., Eaves C.J., Wasserman W.W., Jones S., Huntsman D., Hirst M., Caldas C., Marra M.A., Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
30. Tornos C., Soslow R., Chen S., Akram M., Hummer A.J., Abu-Rustum N., Norton L., Tan L.K. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am. J. Surg. Pathol. 2005, 29:1482-1489.
31. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13:e178-185.
32. van de Wiel M.A., Kim K.I., Vosse S.J., van Wieringen W.N., Wilting S.M., Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007, 23:892-894.
33. Wagle N., Berger M.F., Davis M.J., Blumenstiel B., Defelice M., Pochanard P., Ducar M., Van Hummelen P., Macconaill L.E., Hahn W.C., Meyerson M., Gabriel S.B., Garraway L.A. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012, 2:82-93.
34. Weigelt B., Reis Filho J.S. Epistatic interactions and drug response. J. Pathol. 2013, Epub ahead of print. 10.1002/path.4265.
35. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 2012, 4:127ps110.
36. Yates L.R., Campbell P.J. Evolution of the cancer genome. Nat. Rev. Genet. 2012, 13:795-806.